Intelligent system in out-of-hospital management of patients with type 2 diabetes mellitus

doi:10.3969/j.issn.1004-583X.2021.10.012

Abstract

Abstract:

Objective To observe the effectiveness, safety and practicability of smart wearable devices and smart medical mobile phone App software system in out-of-hospital management of patients with type 2 diabetes mellitus(T2DM).Methods Totally 300 patients with type 2 diabetes who were hospitalized in the Department of Endocrinology, People's Hospital of Putuo District, Shanghai from January 2018 to January 2019 were randomly divided into regular group, control group and observation group, 100 cases in each group. The routine group was only given regular discharge health guidance. On the basis of the routine group, the control group was given smart wearable devices and patients managed their lives and monitor indicators by themselves. On the basis of the control group, the observation group installed the smart medical mobile phone App software system, and the medical staff and the patients managed the patients' life and monitored indicators together. The observation continued 3 months to compare blood glucose, blood lipids, body mass index(BMI), 36-Item Short-Form Health Survey(SF-36), Summary of Diabetes Self-Care Activities(SDSCA), and nurses' job satisfaction.Results Compared with regular group, improvement of blood glucose, blood lipids, BMI in observation group and control group were better than that in routine group(P<0.05), and improvement in observation group was significantly better than that in control group(P<0.05). Scores of SF-36, SDSCA and nurses' job satisfaction increased notably in observation group and control group when compared with regular group (P<0.05), and the scores were significantly higher in observation group than in control group (P<0.05).Conclusion For T2DM patients, smart wearable devices and smart medical mobile phone App software system improved quality-of-life, self-management ability, blood glucose, blood lipids and BMI, and raised nurses' job satisfaction.

Key words: diabetes mellitus,type 2, artificial intelligence, blood glucose, cholesterol, quality of life

CLC Number:

R587.1

Yang Xin, Yao Shuyan, Yang Hongjie. Intelligent system in out-of-hospital management of patients with type 2 diabetes mellitus[J]. Clinical Focus, 2021, 36(10): 927-932.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.10.012

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I10/927

Figures/Tables 4

References 20

[1]	Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013,310(9):948-959. doi: 10.1001/jama.2013.168118 URL
[2]	Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years(DA-LYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study2010[J]. Lancet, 2012,380(9859):2197-2223. doi: 10.1016/S0140-6736(12)61689-4 URL
[3]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2010年版)[J]. 中国医学前沿杂志 (电子版), 2011,3(6):54-109.
[4]	乔莉, 李素菡. 互联网健康管理模式对2型糖尿病病人治疗依从性和血糖控制水平的作用观察[J]. 医药前沿, 2020,10(10):236-237.
[5]	董微, 刘延迪, 孙惠杰, 等. 中医情志护理对糖尿病患者生存质量及自我管理能力的影响[J]. 长春中医药大学学报, 2017,33(2):304-306
[6]	张斌. 移动APP应用对2型糖尿病患者自我管理的辅助疗效研究[J]. 中国卫生产业, 2016,13(23):78-80.
[7]	Brady TJ, Murphy L, O'Colmain BJ, et al. A meta-analysis of health status, health behaviors, and healthcare utilization outcomes of the chronic disease self-management program[J]. Prev Chronic Dis, 2013,10:120112. doi: 10.5888/pcd10.120112 URL
[8]	王忠玲, 王雪娇, 林芳荣, 等. 某种移动APP对2型糖尿病患者管理效果研究[J]. 科教文汇(中旬刊), 2019,5(46):115-116.
[9]	宁欣. 中小型城市移动医疗APP应用现状探究——以开封为例[J]. 科技视界, 2020(16):220-222.
[10]	刘洋, 杨添添, 毛敏, 等. 国内移动医疗APP现状调查[J]. 医学信息学杂志, 2018,39(10):7-11.
[11]	Garabedian LF, Ross-Degnan D, Wharam JF. Mobile phone and smart phone technologies for diabetes care and self-management[J]. Curr Diab Rep, 2015,15(12):109. doi: 10.1007/s11892-015-0680-8 URL
[12]	中国互联网络信息中心. 中国互联网络发展状况统计报告 [R]. 北京:中国互联网络信息中心, 2016.
[13]	姚佳, 高阳, 陈秋. 应用移动APP管理妊娠期糖尿病的多维度疗效评价[J]. 世界最新医学信息文摘, 2019,19(50):76-78.
[14]	管丽萍, 王核核, 牛顺平. 个体化糖尿病教育对2型糖尿病患者自我管理能力及血糖控制的影响效果分析[J]. 当代医学, 2019,25(34):185-187.
[15]	潘卫宇, 袁梅梅, 寇晓平, 等. 应用3D打印技术对严重骨缺损患者行髋关节翻修术的护理[J]. 中华护理杂志, 2016,51(9):1064-1067.
[16]	大卫·巴尔的摩. 基因治疗手段将像IT技术一样改变未来[N]. 科技日报, 2016-11-7(4).
[17]	杨小丽, 封欣蔚. 我国移动医疗服务发展的问题与对策分析[J]. 医学与哲学(A), 2016,37(5):1-4+38.
[18]	Robben SH, Perry M, Huisjes M, et al. Implementation of an innovative web-based conference table for community-dwelling frail older people, their informal caregivers and professionals: A process evaluation[J]. BMC Health Serv Res, 2012,12:251. doi: 10.1186/1472-6963-12-251 pmid: 22894654
[19]	Greysen SR, Khanna RR, Jacolbia R, et al. Tablet computers for hospitalized patients: A pilot study to improve inpatient engagement[J]. J Hosp Med, 2014,9(6):396-399. doi: 10.1002/jhm.2169 pmid: 24523051
[20]	李莹, 谭进, 钟代笛, 等. 中国糖尿病自主管理应用程序现状分析[J]. 北京生物医学工程, 2016,35(3):283-289.

组别	例数	FBG(mmol/L)				2 hPPG(mmol/L)					HbA₁c(%)
组别	例数	干预前		干预后		干预前		干预后			干预前		干预后
常规组	100	9.48±2.65		7.84±1.66^△		15.22±2.91		10.35±1.96^△			9.49±2.18		8.17±1.64^△
对照组	100	9.51±2.72		6.43±0.84^△*		15.31±2.78		8.46±1.37^△*			9.65±2.31		7.05±1.27^△*
观察组	100	9.62±2.54		5.51±0.90^△*#		15.19±2.80		7.10±1.15^△*#			9.71±1.99		6.21±0.98^△*#
统计值		F=0.713		F=7.415		F=0.660		F=13.216			F=0.709		F=7.320
P值		0.494		0.001		0.521		0.000			0.494		0.001
组别	例数	HbA₁c达标率[例(%)]				低血糖发生率[例(%)]					BMI(kg/m²)
组别	例数	干预前		干预后		干预前			干预后		干预前		干预后
常规组	100	38(38.0)		47(47.0)^△		2(2.0)			2(2.0)		25.74±2.78		23.17±1.95^△
对照组	100	38(38.0)		61(61.0)^△*		2(2.0)			1(1.0)		25.90±2.61		21.33±2.04^△*
观察组	100	38(38.0)		79(79.0)^△*#		2(2.0)			1(1.0)		25.69±2.62		20.12±1.01^△*#
统计值		χ²=1.130		χ²=19.791		χ²=0.149			χ²=0.521		F=0.981		F=10.174
P值		0.690		0.000		0.709			0.597		0.487		0.000
组别	例数	TG(mmol/L)			TC(mmol/L)				HDL-C(mmol/L)			LDL-C(mmol/L)
组别	例数	干预前	干预后		干预前		干预后		干预前	干预后		干预前		干预后
常规组	100	3.19±1.98	2.23±1.19^△		7.90±1.21		6.19±1.08^△		1.12±0.21	1.26±0.32^△		5.69±1.56		4.08±0.97^△
对照组	100	2.97±2.02	1.94±1.17^△*		7.87±1.25		5.47±0.94^△*		1.01±0.33	1.35±0.18^△*		5.81±1.40		3.14±0.76^△*
观察组	100	3.20±1.81	1.51±0.88^△*#		7.79±1.29		4.61±0.72^△*#		1.02±0.40	1.49±0.56^△*#		5.75±1.64		2.41±0.56^△*#
统计值		F=0.541	F=5.252		F=0.498		F=10.179		F=2.868	F=3.341		F=0.691		F=9.849
P值		0.596	0.008		0.601		0.000		0.065	0.042		0.498		0.000

组别	例数	FBG(mmol/L)				2 hPPG(mmol/L)					HbA₁c(%)
组别	例数	干预前		干预后		干预前		干预后			干预前		干预后
常规组	100	9.48±2.65		7.84±1.66^△		15.22±2.91		10.35±1.96^△			9.49±2.18		8.17±1.64^△
对照组	100	9.51±2.72		6.43±0.84^△*		15.31±2.78		8.46±1.37^△*			9.65±2.31		7.05±1.27^△*
观察组	100	9.62±2.54		5.51±0.90^△*#		15.19±2.80		7.10±1.15^△*#			9.71±1.99		6.21±0.98^△*#
统计值		F=0.713		F=7.415		F=0.660		F=13.216			F=0.709		F=7.320
P值		0.494		0.001		0.521		0.000			0.494		0.001
组别	例数	HbA₁c达标率[例(%)]				低血糖发生率[例(%)]					BMI(kg/m²)
组别	例数	干预前		干预后		干预前			干预后		干预前		干预后
常规组	100	38(38.0)		47(47.0)^△		2(2.0)			2(2.0)		25.74±2.78		23.17±1.95^△
对照组	100	38(38.0)		61(61.0)^△*		2(2.0)			1(1.0)		25.90±2.61		21.33±2.04^△*
观察组	100	38(38.0)		79(79.0)^△*#		2(2.0)			1(1.0)		25.69±2.62		20.12±1.01^△*#
统计值		χ²=1.130		χ²=19.791		χ²=0.149			χ²=0.521		F=0.981		F=10.174
P值		0.690		0.000		0.709			0.597		0.487		0.000
组别	例数	TG(mmol/L)			TC(mmol/L)				HDL-C(mmol/L)			LDL-C(mmol/L)
组别	例数	干预前	干预后		干预前		干预后		干预前	干预后		干预前		干预后
常规组	100	3.19±1.98	2.23±1.19^△		7.90±1.21		6.19±1.08^△		1.12±0.21	1.26±0.32^△		5.69±1.56		4.08±0.97^△
对照组	100	2.97±2.02	1.94±1.17^△*		7.87±1.25		5.47±0.94^△*		1.01±0.33	1.35±0.18^△*		5.81±1.40		3.14±0.76^△*
观察组	100	3.20±1.81	1.51±0.88^△*#		7.79±1.29		4.61±0.72^△*#		1.02±0.40	1.49±0.56^△*#		5.75±1.64		2.41±0.56^△*#
统计值		F=0.541	F=5.252		F=0.498		F=10.179		F=2.868	F=3.341		F=0.691		F=9.849
P值		0.596	0.008		0.601		0.000		0.065	0.042		0.498		0.000

组别	例数	情感指数		健康指数		生活满意度
组别	例数	干预前	干预后	干预前	干预后	干预前	干预后
常规组	100	4.91±1.32	5.57±1.46^△	7.72±2.20	8.19±2.57^△	6.21±1.72	8.39±2.14^△
对照组	100	4.80±1.51	7.19±1.76^△*	7.81±2.32	10.94±2.33^△*	6.32±1.91	10.16±2.34^△*
观察组	100	4.72±1.60	8.99±1.57^△*#	7.69±2.41	12.78±2.69^△*#	6.19±1.83	12.68±2.46^△*#
F值		0.669	13.331	0.701	15.167	0.681	14.771
P值		0.520	0.000	0.495	0.000	0.509	0.000

组别	例数	情感指数		健康指数		生活满意度
组别	例数	干预前	干预后	干预前	干预后	干预前	干预后
常规组	100	4.91±1.32	5.57±1.46^△	7.72±2.20	8.19±2.57^△	6.21±1.72	8.39±2.14^△
对照组	100	4.80±1.51	7.19±1.76^△*	7.81±2.32	10.94±2.33^△*	6.32±1.91	10.16±2.34^△*
观察组	100	4.72±1.60	8.99±1.57^△*#	7.69±2.41	12.78±2.69^△*#	6.19±1.83	12.68±2.46^△*#
F值		0.669	13.331	0.701	15.167	0.681	14.771
P值		0.520	0.000	0.495	0.000	0.509	0.000

组别	例数	饮食控制		运动管理		血糖监测
组别	例数	干预前	干预后	干预前	干预后	干预前	干预后
常规组	100	1.89±0.67	3.75±0.92^△	2.21±0.43	4.12±0.46^△	1.91±0.61	3.81±0.57^△
对照组	100	1.88±0.69	4.97±0.86^△*	2.23±0.41	5.36±0.48^△*	1.94±0.65	5.11±0.59^△*
观察组	100	1.87±0.68	6.49±0.61^△*#	2.24±0.45	6.57±0.49^△*#	1.93±0.63	6.42±0.61^△*#
F值		0.151	8.969	0.481	8.129	0.169	8.971
P值		0.712	0.000	0.640	0.000	0.710	0.000
组别	例数	足部干预		合理用药		SDSCA总分
组别	例数	干预前	干预后	干预前	干预后	干预前	干预后
常规组	100	2.87±0.79	4.39±0.54^△	1.71±0.69	3.64±0.98^△	10.59±1.65	19.71±1.96^△
对照组	100	2.91±0.67	5.27±0.57^△*	1.70±0.71	4.85±0.97^△*	10.66±1.64	25.56±2.06^△*
观察组	100	2.89±0.71	6.69±0.46^△*#	1.69±0.75	6.71±0.96^△*#	10.62±1.73	32.88±2.17^△*#
F值		0.519	8.109	0.141	10.157	0.708	18.961
P值		0.598	0.000	0.716	0.000	0.494	0.000